Is 5-24-04-00350 (Beilstein Handbook Reference) Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 5-24-04-00350 (Beilstein Handbook Reference)? Is 5-24-04-00350 (Beilstein Handbook Reference) safe for nursing mother and child? Does 5-24-04-00350 (Beilstein Handbook Reference) extracts into breast milk? Does 5-24-04-00350 (Beilstein Handbook Reference) has any long term or short term side effects on infants? Can 5-24-04-00350 (Beilstein Handbook Reference) influence milk supply or can 5-24-04-00350 (Beilstein Handbook Reference) decrease milk supply in lactating mothers?

• DrLact safety Score for 5-24-04-00350 (Beilstein Handbook Reference) is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of 5-24-04-00350 (Beilstein Handbook Reference) may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that 5-24-04-00350 (Beilstein Handbook Reference) may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using 5-24-04-00350 (Beilstein Handbook Reference) .
• It is recommended to evaluate the advantage of not breastfeeding while using 5-24-04-00350 (Beilstein Handbook Reference) Vs not using 5-24-04-00350 (Beilstein Handbook Reference) And continue breastfeeding.
• While using 5-24-04-00350 (Beilstein Handbook Reference) Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Eventual and low dose use of benzodiacepines are compatible with breastfeeding. Use the short-acting benzodiazepine and minimal effective dose as possible mostly in the neonatal period. Follow-up for sedation and feeding ability of the infant. Bed-sharing is not recommended for mothers who are taking this medication.

5-24-04-00350 (Beilstein Handbook Reference) is not approved for marketing in the United States by the U.S. Food and Drug Administration. It is excreted into breastmilk and, because of its long half-life of about 20 hours, it may accumulate in the serum of breastfed infants with repeated doses. Other agents are preferred, especially while nursing a newborn or preterm infant. After a single dose of 5-24-04-00350 (Beilstein Handbook Reference), as for sedation before a procedure, there is usually no need to wait to resume breastfeeding, although with a newborn or preterm infant, a cautious approach would be to wait a period of 6 to 8 hours before resuming nursing.